Research member at the Institute, Marie-Claude Bourgeois-Daigneault, and her team at the CRCHUM have published a study in Nature Communications showing how they have succeeded in creating a personalized, effective and anti-cancer-specific vaccine. 

The vaccine combines oncolytic viruses with small synthetic molecules (peptides) specific to the targeted cancer. It allows it to attack the cancer both by killing it directly and by inducing an immune response through the virus. The effectiveness of the immunization has been demonstrated in an animal model. 

To read the full news, click here.